Patients With Newly Diagnosed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Study: Chemotherapy, Pembrolizumab Adjuvant Therapy Did Not Improve Disease-Free Survival for Endometrial Cancer

Study: Chemotherapy, Pembrolizumab Adjuvant Therapy Did Not Improve Disease-Free Survival for Endometrial Cancer
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.

United statesGursel aktanMerck research laboratoriesAmerican cancer societyProvides updateEvaluating keytrudaPatients with newly diagnosedKey statisticsUpdated januaryLenvatinib combination therapyAdvanced endometrial

D-VRd Improves PFS in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant, daratumumab, bortezomib, lenalidomide, and dexamethasone consolidation and daratumumab/lenalidomide maintenance prolonged progression-free survival in patients with newly diagnosed, transplant-eligible multiple myeloma.

Subcutaneous daratumumabAutologous stem cell transplantNd dexamethasone consolidationDaratumumab lenalidomide maintenancePatients with newly diagnosedTransplant eligible multiple myelomaPerseus trialPieter sonneveldErasmus mc cancer institute

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

Treatment with the combination of isatuximab, carfilzomib, lenalidomide, and dexamethasone generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.

Dana farber cancer instituteUnited statesNordrhein westfalenLisa leypoldtDepartment of medicine at harvard medical schoolBristol myers squibbUniversity medical center hamburgInternational staging scoreInternational myeloma society annual meetingMyeloma society annual meetingUniversity medical center hamburg eppendorfMedical oncologyHarvard medical schoolSecond revisionNd dexamethasonePatients with newly diagnosed

FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML

Dr Sekeres discusses the FDA approval of quizartinib plus chemotherapy in patients with newly diagnosed, FLT3-ITD–positive AML, key efficacy and safety data from the QuANTUM-First trial, and how this quizartinib regimen addresses an unmet need for older patients in this population.

University of miamiUnited statesAshling wahnerMikkaela sekeresUniversity of miami health systemDivision of hematologyLeukemia sectionMiami health systemApple podcastsGoogle podcastsAmazon musicFda approval of quizartinib in combination with chemotherapyPatients with newly diagnosedLt3 itd positive acute myeloid leukemiaThe university of miami health systemQuantum first trial

Durvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial Cancer

The combination of durvalumab and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus olaparib or durvalumab alone, elicited a statistically significant and clinically meaningful improvement in progression-free survival in patients with newly diagnosed, advanced or recurrent endometrial cancer.

United statesSusan galbraithShannonn westinUniversity of texas md anderson cancer centerGynecologic oncologyReproductive medicineCancer centerThe combination of durvalumab and platinum based chemotherapyDurvalumab plus olaparibPatients with newly diagnosedAdvanced or recurrent endometrial cancerDuoe trialThe university of texas md anderson cancer center